Cyanocobalamin Injection, USP

Manufacturer
Asclemed USA, Inc. | ASCLEMED USA INC. DBA ENOVACHEM
Effective date
2021-07-08
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:37:20

Label at a glance#

ProductCyanocobalamin
Active ingredientCYANOCOBALAMIN
Label structure12 sections

Indications and uses

Cyanocobalamin is indicated for Vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions:             Addisonian (pernicious) anemia             Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy             Fish tapeworm infestation             Malignancy of pancreas ...

Dosage and administration

Avoid using the intravenous route.  Use of this product intravenously will result in almost all of the vitamin being lost in the urine. Parenteral Vitamin B 12 is the recommended treatment and will be required for the remainder of the patient’s life.  The oral form is not dependable.  A dose of 100 mcg daily for six or seven days should be administered by intramuscular or deep subcutaneous injection.  If there is ...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Cyanocobalamin Injection, USP is a sterile solution of cyanocobalamin for intramuscular or subcutaneous use.

Each mL contains 1000 mcg cyanocobalamin; sodium chloride 0.9%; benzyl alcohol 1.5%; Water for Injection q.s.  Hydrochloric acid and/or sodium hydroxide for pH adjustment if necessary (4.5-7.0).

Cyanocobalamin appears as dark, red crystals or as an amorphous or crystalline, red powder.  It is very hygroscopic in the anhydrous form, and sparingly soluble in water (1:80).  It is stable to autoclaving for short periods at 121°C.  The Vitamin B 12 coenzymes are very unstable in light.

The chemical name is 5,6-dimethyl-benzimidazolyl cyanocobamide.  The cobalt content is 4.34%.  The structural formula is represented below:

structurestructure


CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Vitamin B 12 is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis.

Cyanocobalamin is quantitatively and rapidly absorbed from intramuscular and subcutaneous sites of injection; the plasma level of the compound reaches its peak within one hour after intramuscular injection. Absorbed Vitamin B 12 is transported via specific B 12 binding proteins, transcobalamin I and II to the various tissues.  The liver is the main organ for Vitamin B 12 storage.

Within 48 hours after injection of 100 or 1000 mcg of Vitamin B 12, 50 to 98% of the injected dose may appear in the urine.  The major portion is excreted within the first eight hours. Intravenous administration results in even more rapid excretion with little opportunity for liver storage.

Gastrointestinal absorption of Vitamin B 12 depends on the presence of sufficient intrinsic factor and calcium ions.  Intrinsic factor deficiency causes pernicious anemia, which may be associated with subacute combined degeneration of the spinal cord.  Prompt parenteral administration of Vitamin B 12 prevents progression of neurologic damage.

The average diet supplies about 5 to 15 mcg/day of Vitamin B 12 in a protein-bound form that is available for absorption after normal digestion.  Vitamin B 12 is not present in foods of plant origin, but is abundant in foods of animal origin.  In people with normal absorption, deficiencies have been reported only in strict vegetarians who consume no products of animal origin (including no milk products or eggs).

Vitamin B 12 is bound to intrinsic factor during transit through the stomach; separation occurs in the terminal ileum in the presence of calcium, and Vitamin B 12 enters the mucosal cell for absorption.  It is then transported by the transcobalamin binding proteins.  A small amount (approximately 1% of the total amount ingested) is absorbed by simple diffusion, but this mechanism is adequate only with very large doses.  Oral absorption is considered too undependable to rely on in patients with pernicious anemia or other conditions resulting in malabsorption of Vitamin B 12.

Cyanocobalamin is the most widely used form of Vitamin B 12, and has hematopoietic activity apparently identical to that of the antianemia factor in purified liver extract.  Hydroxocobalamin is equally as effective as cyanocobalamin, and they share the cobalamin molecular structure.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Cyanocobalamin is indicated for Vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions:

            Addisonian (pernicious) anemia

            Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy

            Fish tapeworm infestation

            Malignancy of pancreas or bowel

            Folic acid deficiency


It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue.  Such measures remove the need for long-term administration of cyanocobalamin.

Requirements of Vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation.

Cyanocobalamin injection is also suitable for the Vitamin B 12 absorption test (Schilling test).

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Sensitivity to cobalt and/or Vitamin B 12 is a contraindication.

WARNINGS

WARNINGS SECTION

WARNING: This product contains aluminum that may be toxic.  Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired.  Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity.  Tissue loading may occur at even lower rates of administration.

Patients with early Leber’s disease (hereditary optic nerve atrophy) who were treated with cyanocobalamin suffered severe and swift optic atrophy.

Hypokalemia and sudden death may occur in severe megaloblastic anemia which is treated intensely.

Anaphylactic shock and death have been reported after parenteral Vitamin B 12 administration.  An intradermal test dose is recommended before cyanocobalamin injection is administered to patients suspected of being sensitive to this drug.

This product contains benzyl alcohol.  Benzyl alcohol has been reported to be associated with a fatal ‘‘Gasping Syndrome’’ in premature infants.

PRECAUTIONS

PRECAUTIONS SECTION

General

PRECAUTIONS SECTION

Vitamin B 12 deficiency that is allowed to progress for longer than three months may produce permanent degenerative lesions of the spinal cord.  Doses of folic acid greater than 0.1 mg/day may result in hematologic remission in patients with Vitamin B 12 deficiency.  Neurologic manifestations will not be prevented with folic acid, and if not treated with Vitamin B 12, irreversible damage will result.

Doses of cyanocobalamin exceeding 10 mcg daily may produce hematologic response in patients with folate deficiency.  Indiscriminate administration may mask the true diagnosis.

Information for Patients

PRECAUTIONS SECTION

Patients with pernicious anemia should be instructed that they will require monthly injections of Vitamin B 12 for the remainder of their lives.  Failure to do so will result in return of the anemia and in development of incapacitating and irreversible damage to the nerves of the spinal cord.  Also, patients should be warned about the danger of taking folic acid in place of Vitamin B 12, because the former may prevent anemia but allow progression of subacute combined degeneration.

A vegetarian diet which contains no animal products (including milk products or eggs) does not supply any Vitamin B 12.  Patients following such a diet should be advised to take oral Vitamin B 12 regularly.  The need for Vitamin B 12 is increased by pregnancy and lactation.  Deficiency has been recognized in infants of vegetarian mothers who were breast fed, even though the mothers had no symptoms of deficiency at the time.

Laboratory Tests

PRECAUTIONS SECTION

During the initial treatment of patients with pernicious anemia, serum potassium must be observed closely the first 48 hours and potassium replaced if necessary.

Hematocrit, reticulocyte count, Vitamin B 12, folate and iron levels should be obtained prior to treatment.  Hematocrit and reticulocyte counts should be repeated daily from the 5th to 7th days of therapy and then frequently until the hematocrit is normal.  If folate levels are low, folic acid should also be administered.  If reticulocytes have not increased after treatment or if reticulocyte counts do not continue at least twice normal as long as the hematocrit is less than 35%, diagnosis or treatment should be reevaluated.  Repeat determinations of iron and folic acid may reveal a complicating illness that might inhibit the response of the marrow.

Patients with pernicious anemia have about three times the incidence of carcinoma of the stomach as the general population, so appropriate tests for this condition should be carried out when indicated.

Drug/Laboratory Test Interactions

PRECAUTIONS SECTION

Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and Vitamin B 12 diagnostic blood assays.

Colchicine, para-aminosalicylic acid and heavy alcohol intake for longer than two weeks may produce malabsorption of Vitamin B 12.

Carcinogenesis, Mutagenesis

PRECAUTIONS SECTION

Long-term studies in animals to evaluate carcinogenic potential have not been done.  There is no evidence from long-term use in patients with pernicious anemia that cyanocobalamin is carcinogenic.  Pernicious anemia is associated with an increased incidence of carcinoma of the stomach, but this is believed to be related to the underlying pathology and not to treatment with cyanocobalamin.

Pregnancy

PRECAUTIONS SECTION

Pregnancy Category C—Adequate and well-controlled studies have not been done in pregnant women.  However, Vitamin B 12 is an essential vitamin and requirements are increased during pregnancy.  Amounts of Vitamin B 12 that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for pregnant women (4 mcg daily) should be consumed during pregnancy.

Nursing Mothers

PRECAUTIONS SECTION

Vitamin B 12 is known to be excreted in human milk.  Amounts of Vitamin B 12 that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for lactating women (4 mcg daily) should be consumed during lactation .

Pediatric Use

PRECAUTIONS SECTION

Intake in children should be in the amount (0.5 to 3 mcg daily) recommended by the Food and Nutrition Board, National Academy of Science-National Research Council.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Generalized

ADVERSE REACTIONS SECTION

Anaphylactic shock and death have been reported with administration of parenteral Vitamin B 12 (see WARNINGS).

Cardiovascular

ADVERSE REACTIONS SECTION

Pulmonary edema and congestive heart failure early in treatment; peripheral vascular thrombosis.

Hematological

ADVERSE REACTIONS SECTION

Polycythemia vera.

Gastrointestinal

ADVERSE REACTIONS SECTION

Mild transient diarrhea.

Dermatological

ADVERSE REACTIONS SECTION

Itching; transitory exanthema.

Miscellaneous

ADVERSE REACTIONS SECTION

Feeling of swelling of entire body.

OVERDOSAGE

OVERDOSAGE SECTION

No overdosage has been reported with this drug.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Avoid using the intravenous route.  Use of this product intravenously will result in almost all of the vitamin being lost in the urine.

Pernicious Anemia

DOSAGE & ADMINISTRATION SECTION

Parenteral Vitamin B 12 is the recommended treatment and will be required for the remainder of the patient’s life.  The oral form is not dependable.  A dose of 100 mcg daily for six or seven days should be administered by intramuscular or deep subcutaneous injection.  If there is clinical improvement and if a reticulocyte response is observed, the same amount may be given on alternate days for seven doses, then every three to four days for another two to three weeks.  By this time hematologic values should have become normal.  This regimen should be followed by 100 mcg monthly for life.  Folic acid should be administered concomitantly if needed.

Patients With Normal Intestinal Absorption

DOSAGE & ADMINISTRATION SECTION

Where the oral route is not deemed adequate, initial treatment similar to that for patients with pernicious anemia may be indicated depending on the severity of the deficiency.  Chronic treatment should be with an oral B 12 preparation.  If other vitamin deficiencies are present, they should be treated.

Schilling test

DOSAGE & ADMINISTRATION SECTION

The flushing dose is 1000 mcg.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

HOW SUPPLIED SECTION

Cyanocobalamin Injection, USP is supplied as follows:

Unit of SaleStrengthEach

NDC NDC 76420-111-25

(relabeled from NDC 63323-044-01)

Unit of 25

1,000 mcg per mL
1 mL fill in a 2 mL vial
1 mL Multiple Dose Vial 

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

PROTECT FROM LIGHT.

Use only if solution is clear and seal intact.

SPL UNCLASSIFIED SECTION

Relabeled by:

Enovachem PHARMACEUTICALS
Torrance, CA 90501

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

traytray

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309594cyanocobalamin 1000 MCG/ML Injectable SolutionPSN1
309594vitamin B12 1 MG/ML Injectable SolutionSCD1
309594cyanocobalamin 1 MG/ML Injectable SolutionSY1
309594cyanocobalamin 1000 MCG/ML Injectable SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CYANOCOBALAMIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b82b4008-22fd-05f5-6cc6-c0a6e81c65b8Product name220240805
d206bb34-ea65-399d-70d9-834f22dc2c18Product name320170724

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
76420-111-25Cyanocobalamin1 mL in 1 VIAL, MULTI-DOSEINJECTION, SOLUTION11
76420-111-25Cyanocobalamin25 in 1 TRAYINJECTION, SOLUTION251

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
76420-111CYANOCOBALAMIN INJECTION, SOLUTION [ASCLEMED USA, INC.]1Current NDC, Legacy NDC, 2 package rows20210710_66e3441f-79fa-4a1b-be22-2bc683cd7abc.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
63323-044-00ML - Milliliter63323-0447c5040c2-0354-43d8-8ebb-8a27739fae5212019-10-07
63323-044-01ML - Milliliter63323-0442ed89db3-669d-4f3f-8ce0-e54f60e1cc8a12012-07-24
63323-044-41ML - Milliliter63323-044ab4fa83b-78e6-4dce-82c3-0de939a7301a12019-03-12
63323-044-44ML - Milliliter63323-044eccf56c0-c974-4c3a-adaf-0aafd7f3dceb12019-03-12

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
76420-11176420-111-25
63323-044

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A080557-002CYANOCOBALAMINCYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 1982
A080557-003VIBISONECYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A080557-003AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 19822680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 19825bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 1982d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 1982d06236e962d9…
2024-10-29 15:01 UTC2024-10A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 198279d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 1982301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 19821e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 19828072bd15b7f6…
2024-05-31 18:47 UTC2024-05A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 19825c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 19825d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 19824b0b4de00fa7…
2022-04-04 05:41 UTC2022-04A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A080557-002CYANOCOBALAMIN0.1MG/MLINJECTABLE / INJECTIONApproved before 198274a2ff9319b5…
2019-12-13 00:20 UTC2019-12A080557-003VIBISONE1MG/MLINJECTABLE / INJECTIONAPRS, Approved before 198274a2ff9319b5…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A080557-003AP184e616aacf4f…
2026-08-18 06:07:402026-07A080557-003AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A080557-003AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A080557-003AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08A080557-003AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A080557-003AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A080557-003AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A080557-003AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A080557-003AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A080557-003AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A080557-003AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A080557-003AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A080557-003AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A080557-003AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A080557-003AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A080557-003AP18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A080557-003AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A080557-003AP15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A080557-003AP14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A080557-003AP174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A080557-003AP1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A080557-003AP1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A080557-003AP187673890dc5c…
2021-03-12 10:30 UTC2021-03A080557-003AP15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A080557-003AP18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A080557-003AP1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A080557-003AP13f01610625f2…
2019-09-15 20:21 UTC2019-09A080557-003AP1b00525d2431f…
2019-07-19 19:46 UTC2019-07A080557-003AP1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A080557-003AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A080557-003AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A080557-003AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A080557-003AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A080557-003AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A080557-003AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A080557-003AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05A080557-003AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01A080557-003AP13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A080557-003AP13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A080557-003AP1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 3 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CyanocobalaminCYANOCOBALAMINFresenius Kabi USA, LLCacff4ff3-4435-4995-a117-dbfcdf72334a2024-12-15Warnings, Adverse reactionsExact identifier
ndc (product): 63323-044
CyanocobalaminCYANOCOBALAMINFresenius Kabi USA, LLC8b1cdee5-3368-40e4-90bf-31a64df1f38a2024-12-12Warnings, Adverse reactionsExact identifier
ndc (product): 63323-044
CyanocobalaminCYANOCOBALAMINAsclemed USA, Inc.66e3441f-79fa-4a1b-be22-2bc683cd7abc2021-07-08Warnings, Adverse reactionsExact identifier
ndc (package): 76420-111-25
ndc (product): 76420-111
ndc11 (package): 76420011125
spl id: c6976242-83a1-4644-e053-2995a90a0904
spl set id: 66e3441f-79fa-4a1b-be22-2bc683cd7abc

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.